Evidence map›Paper›PMID 38523630›Full record

ReviewCurrent surgery reports2024

Innovations in Molecular Biomarkers and Biomaterial-Based Immunotherapies for Head & Neck Cancer.

Sarah Anne Wong, Victoria A Manon, Simon Young, Chi T Viet

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current surgery reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Sarah Anne WongSchool of Medicine, Orthopaedic Trauma Institute, University of California San Francisco, 2550 23rd St., Bldg. 9, 3rd Floor, San Francisco, CA 94110 USA.
Victoria A ManonBernard and Gloria Pepper Katz Department of Oral and Maxillofacial Surgery, The University of Texas Health Science Center at Houston School of Dentistry, 7500 Cambridge Street, Suite 6510, Houston, TX 77054 USA.
Simon YoungBernard and Gloria Pepper Katz Department of Oral and Maxillofacial Surgery, The University of Texas Health Science Center at Houston School of Dentistry, 7500 Cambridge Street, Suite 6510, Houston, TX 77054 USA.
Chi T VietDepartment of Oral and Maxillofacial Surgery, Loma Linda University School of Dentistry, 11092 Anderson St., Loma Linda, CA 92350 USA.
The University of Texas Health Science Center at Houston · USLoma Linda University · USUniversity of California, San Francisco · US

Funding

The REASON Score: An Epigenetic And Clinicopathologic Score to Predict Risk of Poor Survival in Early Stage Oral Squamous Cell Carcinoma PatientsR01DE031395 · NIDCR · LOMA LINDA UNIVERSITY · PI Chi T. Viet · 2022 to 2026
$3.7M
SynerGel: A Novel Tumor Microenvironment-Modulating Hydrogel for Local ImmunotherapyR01DE030140 · NIDCR · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI YOUNG, SIMON · 2021 to 2025
$3.0M
Clinical study to evaluate the methylation signature of head and neck squamous cell carcinoma painK23DE030250 · NIDCR · LOMA LINDA UNIVERSITY · PI VIET, CHI T. · 2021 to 2025
$865k
NIDCR NIH HHS K23 DE030250NIDCR NIH HHS R01 DE030140NIDCR NIH HHS R01 DE031395
6 · The paper itself

Abstract

Purpose of Review: Oral squamous cell carcinoma (OSCC) survival rates have remained stagnant due to a lack of targeted therapies and diagnostic tools. Patient risk is currently determined solely through clinicopathologic features, primarily tumor staging, which lacks the necessary precision to stratify patients by risk and accurately dictate adjuvant treatment. Similarly, conventional OSCC therapies have well-established toxicities and limited efficacy. Recent Findings: Recent studies show that patient risk can now be assessed using non-invasive techniques, at earlier time points, and with greater accuracy using molecular biomarker panels. Additionally, novel immunotherapies not only utilize the host's immune response to combat disease but also have the potential to form immunological memory to prevent future recurrence. Localized controlled-release formulas have further served to reduce toxicity and allow the de-escalation of other treatment modalities. Summary: We review the latest advances in head and neck cancer diagnosis and treatment, including novel molecular biomarkers and immunotherapies.

Indexed as

BiomarkerBiomaterialsHead and neck cancerImmunotherapyNon-invasive biopsyOral cancer

Identifiers

PMID38523630
PMCPMC10954983
OpenAlexW4392237184

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.